Pomalid (Pomalidomide) 4 mg Capsules

Indicated for the treatment of adult patients with Relapsed and Refractory Multiple Myeloma (RRMM) who:

• Have received at least two prior treatment regimens, including lenalidomide and bortezomib.
• Have demonstrated disease progression on the last therapy.

Must be administered in combination with low-dose Dexamethasone.

Standard Dose: 4 mg capsule.

Treatment Cycle (28 Days):

• 📅 Days 1 to 21: Take 4 mg orally once daily.
• 📅 Days 22 to 28: Rest period (no medication).

⚠️ Handling Instructions:

• 💊 Swallow whole with water. DO NOT BREAK, CHEW, or OPEN capsules. The powder is toxic and teratogenic.
• Take at the same time each day, with or without food.

🚫 BLACK BOX WARNING: PREGNANCY (Category X).

Pomalidomide causes severe life-threatening birth defects. Females of reproductive potential must use two effective forms of contraception starting 4 weeks before therapy.

Other Contraindications:

• Breastfeeding.
• Severe hypersensitivity to pomalidomide.

Serious adverse reactions include:

• Hematologic Toxicity: Severe Neutropenia (low white blood cells) is very common. Weekly blood counts required for the first 8 weeks.
• Venous Thromboembolism: High risk of DVT/PE. Anticoagulant prophylaxis (e.g., Aspirin) is mandatory.
• Infections: Increased risk of pneumonia.
• Fatigue and weakness.